SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
How Biogen Makes Most of Its Cash
Drug Development
A Look at Biogen’s Big Bet on the Holy Grail of Science—Alzheimer’s
March 28, 2017
 · 
2 min read
How Biogen Makes Most of Its Cash
Business
Biogen Loses Gene Therapy Pioneer to REGENXBIO
March 28, 2017
 · 
3 min read
How Biogen Makes Most of Its Cash
Genetown
How Biogen Spinoff Bioverativ and Its Hemophilia Med Could Make This Biotech Bleed
March 23, 2017
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Policy
Biogen’s Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target
March 22, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Genetown
Biogen Faces Biggest One-Day Drop
March 17, 2017
 · 
3 min read
Business
Biogen Faces Another High-Profile Departure
March 8, 2017
 · 
1 min read
Deals
5 Things Biogen’s CEO Just Said That You Don’t Want To Miss
March 8, 2017
 · 
1 min read
Policy
Drug Giants Like Biogen, Vertex to Ignore Investor Calls to Explain Price Hikes
March 2, 2017
 · 
1 min read
A Look Inside Takeda's Remarkable R&D Transformation
Job Trends
Momenta to Become Neighbors With Biogen, Ironwood in Kendall Square Next Year
February 28, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
MS Patients Choose Death Risk With Biogen Idec, Inc. (Massachusetts)'s Potent Drug Treatment
May 23, 2013
 · 
1 min read
Business
Biogen Idec, Inc. (Massachusetts) Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer
May 23, 2013
 · 
1 min read
Genetown
Biogen Idec, Inc. (Massachusetts) to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference
May 23, 2013
 · 
1 min read
Policy
Biogen Idec, Inc. (Massachusetts) Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis
May 21, 2013
 · 
1 min read
Policy
Genentech and Biogen Idec, Inc. (Massachusetts) Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
May 17, 2013
 · 
1 min read
Policy
FDA Accepts Biogen Idec, Inc. (Massachusetts)’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
May 13, 2013
 · 
1 min read
Business
Biogen Idec, Inc. (Massachusetts) to Report First Quarter 2013 Financial Results on April 25, 2013
April 11, 2013
 · 
1 min read
Genetown
Biogen Idec, Inc. (Massachusetts) Exec Explains $55,000 Annual Cost of New Drug
April 5, 2013
 · 
1 min read
Drug Development
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Biogen Idec, Inc. (Massachusetts) Daclizumab HYP in Multiple Sclerosis
April 4, 2013
 · 
1 min read
Deals
Biogen Idec, Inc. (Massachusetts) Completes Purchase of Full Rights and Control of TYSABRI®
April 3, 2013
 · 
1 min read
Load More